American Campus Communities LightView Achieves First Private Student Housing LEED Platinum Green Building Certification in Boston and Announces Renewable Energy Contract businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.
News Category Global Banking & Finance Reviews
Arecor Limited: First Patient Dosed in Phase I Clinical Trial of Ultra-Concentrated Rapid Acting Insulin Candidate, AT278, for Diabetes
CAMBRIDGE, United Kingdom, Dec. 15, 2020 Arecor Limited
(“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives announces dosing of the first patient in a Phase I clinical trial for its second clinical stage product, an ultra-concentrated rapid acting insulin, AT278.
AT278 is a novel proprietary formulation of concentrated insulin (500U/mL) that is designed to maintain rapid-acting characteristics in a reduced volume, thereby enabling fast absorption into the bloodstream from the site of injection.